Mohammad W. Awlad Mohammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammad W. Awlad Mohammad has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alhareth M. Amro
Faculty of Medicine, Al-Quds University, Jerusalem, Palestine
2 shared publications Essa Hasheem
Medical Research Club, Faculty of Medicine, Al-Quds University, Jerusalem, Palestine
2 shared publicationsAbdallah Dwayat
Faculty of Medicine, Al-Quds University
1 shared publicationAbdallah Qawasmeh
Health Education and Scientific Research Unit, Ministry of Health
1 shared publicationAdham Itbaisha
1 shared publicationAhmad W. Awlad Mohammad
Faculty of Medicine, Mansoura University, Dakahlia, Egypt
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Ophthalmology
- Vol. 6, 1953940
Knowledge gaps and practices for glaucoma among adults in Palestine: a cross-sectional study
Background: Glaucoma is a leading cause of irreversible blindness globally, often progressing asymptomatically until advanced stages. Awareness and knowledge of glaucoma are critical determinants of early diagnosis and treatment-seeking behavior. Data on glaucoma awareness in Palestine are scarce. This study aimed to assess the level of awareness, knowledge, and attitudes regarding glaucoma among the general Palestinian population and to identify sociodemographic factors associated with inadequate knowledge. Methods: A population-based cross-sectional study was conducted from December 1 to December 30, 2025, using an online questionnaire distributed to adults (≥18 years) residing in the West Bank and Jerusalem. The questionnaire included sociodemographic information, glaucoma awareness, knowledge, attitudes, and practices. Reliability was assessed using Cronbach’s alpha (α = 0.87). Knowledge scores were calculated with a maximum of 8 points; good knowledge was defined as ≥6 correct answers. Data were analyzed using SPSS v23, employing chi-square tests and multivariable logistic regression. Results: A total of 741 participants completed the survey (50.2% male, 49.8% female). Overall, 54% had heard of glaucoma, but only 13.8% demonstrated good knowledge. Prior awareness of glaucoma was the strongest predictor of good knowledge (aOR = 7.89, p < 0.001). Knowledge gaps were notable regarding the asymptomatic nature of early disease (20.9%), irreversible vision loss (57%), and key risk factors including age ≥40 years (49%), family history (44.9%), and diabetes (55.1%). Older adults, rural residents, and individuals with lower educational levels had significantly lower knowledge scores. Only 26.9% of participants reported eye examinations within the preceding year, and screening intentions were associated with better knowledge (p = 0.015). Conclusions: Although awareness of glaucoma is moderate in Palestine, comprehensive knowledge remains low, particularly among high-risk populations. Public health interventions should target education beyond name recognition, emphasizing asymptomatic progression, irreversible vision loss, and risk factors. Integrating glaucoma education into clinical visits and community-based programs may improve early detection and prevent blindness.
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Ophthalmology
- Vol. 6, 1953940
Open AccessKnowledge gaps and practices for glaucoma among adults in Palestine: a cross-sectional study
Background: Glaucoma is a leading cause of irreversible blindness globally, often progressing asymptomatically until advanced stages. Awareness and knowledge of glaucoma are critical determinants of early diagnosis and treatment-seeking behavior. Data on glaucoma awareness in Palestine are scarce. This study aimed to assess the level of awareness, knowledge, and attitudes regarding glaucoma among the general Palestinian population and to identify sociodemographic factors associated with inadequate knowledge. Methods: A population-based cross-sectional study was conducted from December 1 to December 30, 2025, using an online questionnaire distributed to adults (≥18 years) residing in the West Bank and Jerusalem. The questionnaire included sociodemographic information, glaucoma awareness, knowledge, attitudes, and practices. Reliability was assessed using Cronbach’s alpha (α = 0.87). Knowledge scores were calculated with a maximum of 8 points; good knowledge was defined as ≥6 correct answers. Data were analyzed using SPSS v23, employing chi-square tests and multivariable logistic regression. Results: A total of 741 participants completed the survey (50.2% male, 49.8% female). Overall, 54% had heard of glaucoma, but only 13.8% demonstrated good knowledge. Prior awareness of glaucoma was the strongest predictor of good knowledge (aOR = 7.89, p < 0.001). Knowledge gaps were notable regarding the asymptomatic nature of early disease (20.9%), irreversible vision loss (57%), and key risk factors including age ≥40 years (49%), family history (44.9%), and diabetes (55.1%). Older adults, rural residents, and individuals with lower educational levels had significantly lower knowledge scores. Only 26.9% of participants reported eye examinations within the preceding year, and screening intentions were associated with better knowledge (p = 0.015). Conclusions: Although awareness of glaucoma is moderate in Palestine, comprehensive knowledge remains low, particularly among high-risk populations. Public health interventions should target education beyond name recognition, emphasizing asymptomatic progression, irreversible vision loss, and risk factors. Integrating glaucoma education into clinical visits and community-based programs may improve early detection and prevent blindness.
- Open Access
- 13 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1893092
IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence
Background: IL-17 pathway inhibitors are established treatments for active psoriatic arthritis (PsA), but comparative evidence within this therapeutic class remains limited. We compared the efficacy, safety, treatment rankings, and certainty of evidence for established and emerging IL-17 pathway inhibitors in adults with active PsA. Methods: We conducted a PRISMA-compliant systematic review and network meta-analysis. MEDLINE via PubMed, Embase via Ovid, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trials Register were searched from January 1, 2010, to January 18, 2026. Eligible studies were phase 2 or phase 3 randomized controlled trials in adults with PsA. The primary outcome was ACR50 at Weeks 12–16. Secondary outcomes included ACR20, ACR70, PASI90, minimal disease activity, HAQ-DI, safety outcomes, Week-24 outcomes, and descriptive Week-52 outcomes. Frequentist random-effects network meta-analysis was performed; certainty was assessed using CINeMA. Results: Sixteen RCTs were included. The primary ACR50 network comprised eight RCTs and ten treatment nodes. All active treatments were superior to placebo for ACR50 at Weeks 12–16, with negligible heterogeneity (τ² = 0; I² = 0%) and no important incoherence. Ixekizumab Q2W had the highest ACR50 P-score, followed by bimekizumab 160 mg with loading and ixekizumab Q4W; however, active-treatment confidence intervals overlapped. Secondary outcomes showed consistent improvements in joint, skin, multidomain, and functional endpoints. Sonelokimab and izokibep showed favorable exploratory estimates but very low certainty. Serious adverse events and discontinuations were not clearly increased versus placebo. Bimekizumab showed a modest increase in infection risk and a higher Candida signal; IBD events were rare. Conclusion: IL-17 pathway inhibitors are effective short-term treatments for active PsA. Rankings suggest potential within-class differences, but indirect comparisons and overlapping confidence intervals limit definitive superiority claims. Candida risk and patient-specific factors should inform individualized treatment selection. The protocol was registered in PROSPERO (CRD420251156756). Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251156756 , identifier CRD420251156756.
- 13 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1893092
Open AccessIL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence
Background: IL-17 pathway inhibitors are established treatments for active psoriatic arthritis (PsA), but comparative evidence within this therapeutic class remains limited. We compared the efficacy, safety, treatment rankings, and certainty of evidence for established and emerging IL-17 pathway inhibitors in adults with active PsA. Methods: We conducted a PRISMA-compliant systematic review and network meta-analysis. MEDLINE via PubMed, Embase via Ovid, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trials Register were searched from January 1, 2010, to January 18, 2026. Eligible studies were phase 2 or phase 3 randomized controlled trials in adults with PsA. The primary outcome was ACR50 at Weeks 12–16. Secondary outcomes included ACR20, ACR70, PASI90, minimal disease activity, HAQ-DI, safety outcomes, Week-24 outcomes, and descriptive Week-52 outcomes. Frequentist random-effects network meta-analysis was performed; certainty was assessed using CINeMA. Results: Sixteen RCTs were included. The primary ACR50 network comprised eight RCTs and ten treatment nodes. All active treatments were superior to placebo for ACR50 at Weeks 12–16, with negligible heterogeneity (τ² = 0; I² = 0%) and no important incoherence. Ixekizumab Q2W had the highest ACR50 P-score, followed by bimekizumab 160 mg with loading and ixekizumab Q4W; however, active-treatment confidence intervals overlapped. Secondary outcomes showed consistent improvements in joint, skin, multidomain, and functional endpoints. Sonelokimab and izokibep showed favorable exploratory estimates but very low certainty. Serious adverse events and discontinuations were not clearly increased versus placebo. Bimekizumab showed a modest increase in infection risk and a higher Candida signal; IBD events were rare. Conclusion: IL-17 pathway inhibitors are effective short-term treatments for active PsA. Rankings suggest potential within-class differences, but indirect comparisons and overlapping confidence intervals limit definitive superiority claims. Candida risk and patient-specific factors should inform individualized treatment selection. The protocol was registered in PROSPERO (CRD420251156756). Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251156756 , identifier CRD420251156756.
- Open Access
Disparities in Thoracic Oncology Patients
Background/Objectives: Lung cancer is one of the major causes of mortality worldwide despite breakthroughs in screening, diagnosis, and treatment. These advances have not been evenly spread, and discrepancies between populations remain concerning. This article examines lung cancer discrepancies in epidemiology, risk factors, screening, diagnosis, treatment access and quality, and survival outcomes, and identifies the main causes. Methods: An extensive narrative evaluation of peer-reviewed literature, national cancer surveillance reports, and large population-based research was searched. The evidence on lung cancer disparities by race, ethnicity, socioeconomic status, sex, geography, and healthcare access was synthesized. Disparities in prevention, early identification, treatment, and outcomes were organized into this paper. Results: Lung cancer incidence, stage, treatment, and survival showed persistent differences. Racial and ethnic minority groups, people on low-incomes, uninsured people, and rural or resource-limited people had higher disease burden and worse outcomes. Access to low-dose computed tomography screening, rapid diagnostic follow-up, surgical resection, molecular testing, targeted medicines, immunotherapy, palliative care, and clinical trials was unequal. When guidelines are followed, survival outcomes are similar across races and ethnicities. Conclusions: Lung cancer disparities are mostly caused by structural, social, and healthcare system factors, not biology. Coordinated measures to provide equitable screening, prompt and high-quality treatment, research inclusion, and culturally sensitive and policy-driven actions are needed to enhance lung cancer outcomes.
Open AccessDisparities in Thoracic Oncology Patients
Background/Objectives: Lung cancer is one of the major causes of mortality worldwide despite breakthroughs in screening, diagnosis, and treatment. These advances have not been evenly spread, and discrepancies between populations remain concerning. This article examines lung cancer discrepancies in epidemiology, risk factors, screening, diagnosis, treatment access and quality, and survival outcomes, and identifies the main causes. Methods: An extensive narrative evaluation of peer-reviewed literature, national cancer surveillance reports, and large population-based research was searched. The evidence on lung cancer disparities by race, ethnicity, socioeconomic status, sex, geography, and healthcare access was synthesized. Disparities in prevention, early identification, treatment, and outcomes were organized into this paper. Results: Lung cancer incidence, stage, treatment, and survival showed persistent differences. Racial and ethnic minority groups, people on low-incomes, uninsured people, and rural or resource-limited people had higher disease burden and worse outcomes. Access to low-dose computed tomography screening, rapid diagnostic follow-up, surgical resection, molecular testing, targeted medicines, immunotherapy, palliative care, and clinical trials was unequal. When guidelines are followed, survival outcomes are similar across races and ethnicities. Conclusions: Lung cancer disparities are mostly caused by structural, social, and healthcare system factors, not biology. Coordinated measures to provide equitable screening, prompt and high-quality treatment, research inclusion, and culturally sensitive and policy-driven actions are needed to enhance lung cancer outcomes.